XML 23 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
Mar. 31, 2022
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Cash flows from operating activities:              
Net loss $ (70,575) $ (70,253) $ (50,932) $ (39,805) $ (210,480) $ (128,873)  
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation and amortization expense         19,543 9,330  
Provisions for credit losses         63 401 $ 714
Amortization of deferred contract acquisition costs         1,295 1,254  
Amortization of deferred contract fulfillment costs         452 535  
Accertion of contingent consideration         793 600  
Noncash compensation costs incurred by selling shareholders         5,923 717  
Stock-based compensation expense         48,419 31,756  
Loss on equity method investment 593   554   1,355 2,095  
Deferred income taxes         (1,390) (4,184)  
Changes in operating assets and liabilities, net of acquisition:              
Accounts receivable         4,796 11,325  
Inventories         (439) 28  
Deferred contract acquisition costs         (2,035) (1,053)  
Prepaid expenses and other current assets         (924) 946  
Other assets         (276) 319  
Accounts payable         (5,797) (1,332)  
Accrued expenses and other current liabilities         1,166 (1,564)  
Other long-term liabilities         (25) (1,784)  
Deferred revenue         (18,023) (17,130)  
Net cash used in operating activities         (156,377) (96,614)  
Cash flows from investing activities:              
Purchases of property and equipment         (2) (221)  
Investment in less than majority owned joint venture         (1,960) (2,548)  
Purchases of investments         (499,223)    
Proceeds from sales and maturities of investments         249,855 100,000  
Acquisitions of business, net of cash acquired           (156,526)  
Net cash used in and provided by investing activities         (251,330) (59,295)  
Cash flows from financing activities:              
Proceeds from exercise of common stock options         5,323 18,539  
Proceeds from employee stock purchase plan         2,503 1,599  
Payments for the purchase of treasury stock         (360) (13,988)  
Payment of deferred offering costs           (1,613)  
Proceeds from Section 16(b) disgorgement         295    
Payment of contingent consideration         (11,790)    
Net cash used in and provided by financing activities         (4,029) 4,537  
Effect of exchange rates changes on cash, cash equivalents, and restricted cash         (2,079) (142)  
Net decrease in cash, cash equivalents, and restricted cash         (413,815) (151,514)  
Cash, cash equivalents, and restricted cash at beginning of period   $ 747,211   $ 942,711 747,211 942,711 942,711
Cash, cash equivalents, and restricted cash at end of period 333,396   791,197   333,396 791,197 747,211
Cash, cash equivalents, and restricted cash at end of period:              
Cash and cash equivalents 332,601   790,402   332,601 790,402 746,416
Restricted cash 795   795   795 795  
Total cash, cash equivalents, and restricted cash at end of period $ 333,396   $ 791,197   333,396 791,197 $ 747,211
Supplemental disclosure of cash flow information:              
Cash (refunded) paid for income taxes         1,167 1,414  
Supplemental disclosure of non-cash investing and financing activities:              
Additions to property and equipment included in accrued expenses and accounts payable           312  
Issuance of common stock in settlement of earnout         $ 17,243    
Receivable related to exercise of common stock options           $ 142